This week, Visage Imaging(R), Inc. announced that it has received FDA 510(k) clearance to market its latest thin client product release, Visage CS 3.1. This release brings significant enhancements to its prior offerings in cardiac and other tools, and includes new optional Neuroradiology and Oncology applications.

Enhancements include affordable, optional enterprise-wide access to state-of-the-art applications, including Neuroradiology and Oncology

The Neuro option facilitates brain perfusion analysis in CT and MRI imaging, while the Oncology option provides tools for analyzing, documenting, and comparing lesions for multiple modalities, including Standardized Update Value (SUV)- based analysis for PET-CT.
"Visage Imaging's thin client solution instantly brings workstation-class diagnostic tools to the numerous workplaces of those who need them," Hartmut Schirmacher, Director of Product Management for Visage Imaging, said in a statement. "Compared to typical workstations or other web-based 'fat' solutions, Visage CS offers far superior performance across the board, especially when viewing and processing large data volumes. Furthermore, Visage CS 3.1 will affordably allow for broader access to state-of-the-art applications throughout the enterprise."

In addition to the new application options, Visage CS 3.1 features numerous new and streamlined measurement and post processing tools such as advanced 3D segmentation, ROI-based analysis and time-value curves, and improved editing of cardiac LV models.

More HCB News